Biogen: UBS raises target price to $300 from $270
BIIB•UBS raised its price target for Biogen to $300 from $270.
Related News
Zentek announces annual and special shareholder meeting
ZTEK•
SMB AI adoption outpaces workforce readiness, Insperity research finds
NSP•
Alphabet drags Nasdaq as healthcare, housing and banks shine
GOOGL•
Eli Lilly gains after lifting annual revenue view
LLY•
Novavax earns $125 million milestone as Sanofi launches phase 3 vaccine trial in Europe
NVAX•